|
VKTX
Feb 27, 2019 22:50:46 GMT
JHam likes this
Post by biposter on Feb 27, 2019 22:50:46 GMT
www.fool.com/investing/2019/02/27/is-viking-therapeutics-a-buy.aspx Anyone like VKTX? I think JHam played the data pop last fall? Nice. But it’s all the way back down again. Good TMF article on some of the key NASH stocks. VKTX has a long way to go, with years of dilution ahead, but maybe a good buyout candidate this year from GILD after their recent bomb? Always risky playing for a buyout, but with VKTX probably being the best-in-breed NASH stock, and NASH being a potentially $35B market, and with GILD’s big NASH plans in the tank, probably an acquisition target this year? Or MDGL buyout play instead?
|
|
|
VKTX
Mar 2, 2019 1:24:20 GMT
Post by JHam on Mar 2, 2019 1:24:20 GMT
www.fool.com/investing/2019/02/27/is-viking-therapeutics-a-buy.aspx Anyone like VKTX? I think JHam played the data pop last fall? Nice. But it’s all the way back down again. Good TMF article on some of the key NASH stocks. VKTX has a long way to go, with years of dilution ahead, but maybe a good buyout candidate this year from GILD after their recent bomb? Always risky playing for a buyout, but with VKTX probably being the best-in-breed NASH stock, and NASH being a potentially $35B market, and with GILD’s big NASH plans in the tank, probably an acquisition target this year? Or MDGL buyout play instead? I was following VKTX and wrote about them somewhere on the board, but never pulled the trigger. Thanks for bringing this one up again. I'll have a read of this article in a bit.
|
|
|
Post by biposter on Nov 5, 2019 21:12:45 GMT
So early this year my wag was a possible $VKTX buyout by YE19, but my guess is that it may be pushed back to 1H21. The suitor will probably want confirmed data on NASH, not just for NAFLD. Their Q3 E/R released today says that they completed the required key chronic toxicity studies on their lead drug candidate, VK2809, and submitted that along with their trial data as part of their IND submission to the FDA to initiate their Ph2b study of VK2809 in patients with biopsy-confirmed NASH. But they didn’t give any guidance on trial timeline: when they’d expect to receive FDA green light; enrollment initiation; trial length; interim data readout dates. But here’s a Motley Fool article from a few months back. They expect the next big catalyst will be interim Ph2b data about a year from now. If positive data confirms their Ph2 NAFLD data, then I’m guessing a buyout in 2021. If not, they’d still have to run a large Ph3 before an NDA, so there’s still a very long ways to go. I haven’t been keeping a close eye on data from their competitors recently (I’ve been consumed with bitcoin lol), but there were a slew of NASH failures last year, and I believe VK2809 is still the lead drug candidate in the NASH space, which is a huge unmet need with a $35B market. Risky, but maybe a good time could be next summer (possibly after a raise) to take a position before this much-anticipated NASH interim data readout in 2H20. www.fool.com/investing/2019/08/05/where-will-viking-therapeutics-be-in-1-year.aspx
|
|